Arch Biopartners Inc Asset Resilience Ratio
Arch Biopartners Inc asset resilience ratio. Arch Biopartners Inc (ARCH) has an Asset Resilience Ratio of 69.72% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ARCH cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Arch Biopartners Inc (1999–2023)
Asset resilience ratio of Arch Biopartners Inc from 1999 to 2023. This chart shows how Arch Biopartners Inc's Asset Resilience Ratio has changed over time. Read Arch Biopartners Inc (ARCH) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Arch Biopartners Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Arch Biopartners Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$816.53K | 69.72% |
| Total Liquid Assets | CA$816.53K | 69.72% |
Asset Resilience Insights
- Very High Liquidity: Arch Biopartners Inc maintains exceptional liquid asset reserves at 69.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arch Biopartners Inc Industry Peers by Asset Resilience Ratio
Compare Arch Biopartners Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
Arch Biopartners Inc Asset Resilience Ratio by Year (1999–2023)
Arch Biopartners Inc asset resilience ratio by year from 1999 to 2023. The table below shows the annual Asset Resilience Ratio data for Arch Biopartners Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-09-30 | 69.72% | CA$816.53K ≈ $590.67K |
CA$1.17 Million ≈ $847.21K |
+69.19pp |
| 2000-09-30 | 0.52% | CA$12.40K ≈ $8.97K |
CA$2.37 Million ≈ $1.71 Million |
-3.03pp |
| 1999-09-30 | 3.56% | CA$44.97K ≈ $32.53K |
CA$1.26 Million ≈ $914.95K |
-- |
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more